###begin article-title 0
###xml 89 93 <span type="species:ncbi:10090">mice</span>
Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: implications for cholesterol metabolism
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 1248 1253 1244 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 1253 1256 1249 1252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1257 1259 1253 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 1259 1262 1255 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
###xml 1242 1246 <span type="species:ncbi:10090">mice</span>
Pgp (P-glycoprotein, MDR1, ABCB1) is an energy-dependent drug efflux pump that is a member of the ATP-binding cassette (ABC) family of proteins. Preliminary studies have reported that nonspecific inhibitors of Pgp affect synthesis and esterification of cholesterol, putatively by blocking trafficking of cholesterol from the plasma membrane to the endoplasmic reticulum, and that relative increases in Pgp within a given cell type are associated with increased accumulation of cholesterol. Several key efflux proteins involved in the cholesterol metabolic pathway are transcriptionally regulated by the nuclear hormone liver X receptor (LXR). Therefore, to examine the interplay between P-glycoprotein and the cholesterol metabolic pathway, we utilized a high fat, normal cholesterol diet to upregulate LXRalpha without affecting dietary cholesterol. Our research has demonstrated that mice lacking in P-glycoprotein do not exhibit alterations in hepatic total cholesterol storage, circulating plasma total cholesterol levels, or total cholesterol concentration in the bile when compared to control animals on either a normal (25% calories from dietary fat) or high fat (45% calories from dietary fat) diet. However, p-glycoprotein deficient mice (Mdr1a-/-/1b-/-) exhibit increased hepatic LXRalpha protein expression and an elevation in fecal cholesterol concentration when compared to controls.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
Cholesterol homeostasis of an organism involves the interplay of two main input mechanisms (hepatic and extra-hepatic synthesis of cholesterol, and the intestinal absorption of dietary and biliary cholesterol), balanced with a single elimination pathway via the bile (either through direct excretion into the bile or by conversion to bile acids). Other pathways such as steroidogenesis, myelination and anabolic growth play a minor role in the daily cholesterol balance. Physiologically, an organism has a large but not unlimited capacity to accommodate increases in dietary uptake. When dietary cholesterol levels exceed the capacity of efflux mechanisms and override compensatory decreases in biosynthesis, an imbalance in cholesterol occurs and excessive accumulation ensues.
###end p 4
###begin p 5
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Several key efflux proteins involved in the cholesterol metabolic pathway are transcriptionally regulated by the nuclear hormone liver X receptor (LXR). When stimulated by oxysterols, LXR forms an obligate heterodimer with retinoid X receptor (RXR) and binds to specific DNA response elements, inducing the expression of genes involved in cholesterol efflux pathways [1]. The LXR/RXR dimer can be activated by ligands for either receptor, resulting in a complex interplay between dietary fat and cholesterol induction of the nuclear receptor response [2]. LXRalpha is highly expressed in the liver, and is also found in adipose, intestine, kidney and macrophages, while LXRbeta is ubiquitous.
###end p 5
###begin p 6
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 503 504 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 681 686 681 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 686 689 686 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 690 692 690 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 692 695 692 695 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 908 909 908 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 668 673 <span type="species:ncbi:10090">mouse</span>
###xml 807 811 <span type="species:ncbi:10090">mice</span>
Pgp (P-glycoprotein, MDR1, ABCB1) is an energy-dependent drug efflux pump that is a member of the ATP-binding cassette (ABC) family of proteins [3]. Preliminary studies have reported that nonspecific inhibitors of Pgp inhibit synthesis and esterification of cholesterol, putatively by blocking trafficking of cholesterol from the plasma membrane to the endoplasmic reticulum [4,5], and that relative increases in Pgp within a given cell type are associated with increased accumulation of cholesterol [6,7]. These findings provide indirect evidence supporting a physiologic function for Pgp in the homeostasis of cholesterol. At the whole animal level, a Pgp deficient mouse model (Mdr1a-/-/1b-/-) exhibited a decrease in hepatic cholesterol accumulation and enhanced esterification when compared to control mice. However, these animals did not appear to display any change in dietary cholesterol absorption [8].
###end p 6
###begin p 7
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 260 263 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 264 266 264 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 266 269 266 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 242 247 <span type="species:ncbi:10090">mouse</span>
As much of the evidence surrounding the Pgp and cholesterol interaction is correlative, our analysis was undertaken to establish a specific interface between Pgp function and the cholesterol metabolic pathway. Using a p-glycoprotein knockout mouse model (Mdr1a-/-/1b-/-), we examined the effect of Pgp deficiency on the plasma cholesterol, hepatic cholesterol storage and cholesterol excretion. We then evaluated hepatic LXRalpha expression and downstream targets to shed light on the complex interaction between this membrane-bound protein and cholesterol metabolic pathways. Using dietary fat as a natural LXR ligand, we assessed hepatic LXRalpha expression in animals fed cholesterol-controlled diets (0.02%) corresponding to normal dietary fat content (NF; 25% calories from lipids) and high dietary fat content (HF; 45% calories from lipids).
###end p 7
###begin title 8
Methodology
###end title 8
###begin p 9
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1a</italic>
###xml 72 74 72 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm</italic>
###xml 75 78 75 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bor</italic>
###xml 72 78 72 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm</italic>1<italic>Bor</italic></sup>
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1b</italic>
###xml 84 86 84 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm</italic>
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bor </italic>
###xml 84 91 84 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm</italic>1<italic>Bor </italic></sup>
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Male P-glycoprotein knockout mice in an FVB background (FVB.129P2-Abcb1atm1BorAbcb1btm1Bor N12) and FVB control mice were obtained from Taconic Farms Inc. and maintained for 12 weeks on either a normal fat (NFNC; 25% of calories from fat; n = 8 per genotype) or high fat diet (HFNC; 45% of calories from fat; n = 8 per genotype) containing 0.02% cholesterol (Research Diets). All animal protocols were approved by the University of British Columbia's Animal Care Committee and conform to the Canadian Council on Animal Care guidelines.
###end p 9
###begin title 10
Total cholesterol
###end title 10
###begin p 11
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 145 146 145 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Fecal lipids were extracted using a Folch extraction protocol [9]. Briefly, approximately 100 mg of feces was homogenized for 2 min in a 2:1 CHCl3:CH3OH solution (20:1 chloroform/methanol to fecal mass).
###end p 11
###begin p 12
Homogenates were oscillated overnight at room temperature and then filtered through glass wool. Filtrate was washed with 0.9% saline and centrifuged at 1000 g and 4degreesC for 10 minutes. The upper phase was removed and the interface washed three times with pure upper phase. The lower phase was then dried under nitrogen gas. Lipid films were reconstituted in 300 mul of 10% Triton-X in isopropanol. Total fecal cholesterol levels were then determined using the Wako Cholesterol E assay kit.
###end p 12
###begin title 13
PLTP activity
###end title 13
###begin p 14
Plasma PLTP activity was determined via the transfer of a fluorescent substrate from donor to acceptor (PLTP activity assay kit, Roar Biomedicals). Plasma total cholesterol levels were determined using an enzymatic colorimetric assay (Cholesterol E kit, Wako Chemicals).
###end p 14
###begin title 15
Western blotting (hepatic LXR expression)
###end title 15
###begin p 16
Liver samples weighing 30-50 mg were homogenized in 700 mul of RIPA buffer containing 1 muM PMSF and 1% Protein Inhibitor Cocktail (Sigma). The samples were centrifuged at 14 000 rpm and 4degreesC for 15 minutes and the supernatant was obtained. Protein concentration in each sample was determined using the bicinchoninic acid assay (BCA) (Pierce).
###end p 16
###begin p 17
###xml 577 580 556 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 530 534 <span type="species:ncbi:9925">goat</span>
###xml 540 546 <span type="species:ncbi:9986">rabbit</span>
###xml 558 562 <span type="species:ncbi:9925">goat</span>
###xml 568 573 <span type="species:ncbi:10090">mouse</span>
For LXRalpha protein expression, 130 mug of protein was run on a 1.5 mm thick 12.5%T SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane (Bio-Rad). The membrane was blocked with 5% skim milk in Tris-buffered saline containing 0.1% Tween-20 (TBS-T) for 2 hours at room temperature, cut at the 43 kDa mark, and incubated in primary antibody overnight at 4degreesC (1:500 anti-LXRalpha (Abcam) and 1:300 anti-Histone H1 (Santa Cruz Biotech)). The secondary antibodies were incubated for 1 hour at 4degreesC (1:3000 goat anti-rabbit and 1:3000 goat anti-mouse IgG2A antibody (Santa Cruz Biotech) respectively).
###end p 17
###begin p 18
The membranes were then exposed to ECL western blotting detection reagents (Amersham Biosciences), and band density was determined. Data are expressed as the ratio of LXRalpha to histone protein expression.
###end p 18
###begin title 19
Statistical analyses
###end title 19
###begin p 20
Statistical analyses were conducted using JMP software V 5.1 for Windows (SAS Institute Inc, Carey, NC, USA). A one-way ANOVA was used to establish significant differences between groups, and different group means were then separated by a Tukey-Kramer test for Honestly Significant Difference (HSD); differences were considered statistically significant when P < 0.05.
###end p 20
###begin title 21
Results
###end title 21
###begin title 22
Total cholesterol
###end title 22
###begin p 23
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 5 8 5 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 9 11 9 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 11 15 11 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 238 243 238 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a, b</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 359 362 359 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 363 365 363 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 365 369 365 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
Mdr1a-/-/1b-/- animals on either a NF or HF diet did not exhibit any differences in plasma total cholesterol, hepatic cholesterol storage, or in the concentration of total cholesterol excreted in the bile when compared to wild type (Fig. 1a, b and Fig. 2a). However, a significant difference in fecal total cholesterol levels was observed when comparing Mdr1a-/-/1b-/- animals to wild type (Fig. 2b).
###end p 23
###begin p 24
###xml 114 120 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 120 123 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 124 126 124 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 126 129 126 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 172 175 172 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 176 178 176 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 178 182 178 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 240 245 <span type="species:ncbi:10090">mouse</span>
Total cholesterol storage in plasma (1a) and liver (1b) collected from control and P-glycoprotein deficient mice (Mdr1a/-/-/1b-/-) fed normal fat and high fat diets (Mdr1a/-/-/1b-/- genotype is designated "MDR" in all graphs; FVB wild type mouse is designated "WT"). No significant differences in total cholesterol in the liver or plasma were observed (n = 8; p > 0.05).
###end p 24
###begin p 25
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 119 122 119 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 123 125 123 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 125 128 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 175 177 175 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 177 181 177 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 378 381 378 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 382 384 382 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 384 388 384 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 239 244 <span type="species:ncbi:10090">mouse</span>
Total cholesterol efflux from bile (2a) and feces (2b) collected from control and P-glycoprotein deficient mice (Mdr1a/-/-/1b-/-) fed normal fat and high fat diets (Mdr1a/-/-/1b-/- genotype is designated "MDR" in all graphs; FVB wild type mouse is designated "WT"). No significant differences in total cholesterol in the bile were observed (n = 8; p > 0.05). However, the Mdr1a/-/-/1b-/- genotype was associated with a significant increase in fecal cholesterol concentration (n = 7; p < 0.05). Differing letter designations indicate statistically significant data.
###end p 25
###begin title 26
Hepatic LXR protein expression
###end title 26
###begin p 27
###xml 117 118 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 218 223 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 223 226 215 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 227 229 219 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 229 233 221 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 403 408 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 408 411 392 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 412 414 396 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 414 418 398 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 560 565 540 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 565 568 545 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 569 571 549 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 571 575 551 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
###xml 581 585 <span type="species:ncbi:10090">mice</span>
A significant increase in liver LXRalpha protein expression was found in the HF WT group compared to the NF WT (Fig. 3). There was no significant difference in liver LXRalpha protein expression when comparing diets in Mdr1a-/-/1b-/- animals; however, there was a general trend for increased liver LXRalpha protein expression. A significant increase in liver LXRalpha protein expression was found in the Mdr1a-/-/1b-/- group compared to the WT group in mice fed a NF diet. There was no significant difference in liver LXRalpha protein expression when comparing Mdr1a-/-/1b-/- to WT mice fed a HF diet. No significant difference was seen in the HF diet in LXRalpha expression.
###end p 27
###begin p 28
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 76 78 76 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 78 81 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 179 182 179 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 183 185 183 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 185 189 185 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 336 339 336 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 340 342 340 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 342 345 342 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Hepatic LXRa protein expression in P-glycoprotein deficient mice (Mdr1a/-/-/1b-/-) fed normal and high fat diets. A significant increase in protein expression with both the Mdr1a/-/-/1b-/- genotype and with a high fat diet when compared to wild type animals on a normal fat diet (n = 7; p < 0.05 as noted by asterisk). Placing an Mdr1a/-/-/1b-/-animal on a high fat diet did not result in further upregulation of protein expression.
###end p 28
###begin title 29
Plasma PLTP activity
###end title 29
###begin p 30
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 245 248 245 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 249 251 249 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 251 255 251 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
There was no significant difference in PLTP activity when comparing NF and HF diets; however, there was a general trend for increased PLTP activity in the WT group fed a HF diet (Fig. 4). A significant increase in PLTP activity was seen in Mdr1a-/-/1b-/- mice compared to WT mice fed a NF diet. These findings of increased PLTP activity, contributing to cholesterol clearance, and elevation of plasma HDL, are consistent with the increases in liver LXRalpha protein expression.
###end p 30
###begin p 31
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 93 96 93 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 97 99 97 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 99 102 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Plasma phospholipid transfer protein (PLTP) activity in P-glycoprotein deficient mice (Mdr1a/-/-/1b-/-) fed normal and high fat diets. A significant increase in PLTP activity was associated with the P-glycoprotein deficient genotype (n = 5; p < 0.05). Differing letter designations indicate statistically significant data.
###end p 31
###begin title 32
Hepatic ABCG5 protein expression
###end title 32
###begin p 33
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 7 12 <span type="species:ncbi:10090">mouse</span>
In the mouse liver, the level of ABCG5 cholesterol efflux protein did not show a significant upregulation with genotype or diet (Fig. 5).
###end p 33
###begin p 34
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a/</italic>
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 77 79 77 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 79 82 79 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Hepatic ABCG5 protein expression in P-glycoprotein deficient mice (Mdr1a/-/-/1b-/-) fed normal and high fat diets. No significant differences in ABCG5 levels were observed with change in dietary fat or with genotype (n = 5; p > 0.05).
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 136 144 136 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 240 248 240 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 327 330 327 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 331 333 331 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 333 337 333 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 713 718 713 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 718 721 718 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 722 724 722 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 724 728 724 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 728 732 <span type="species:ncbi:10090">mice</span>
A connection between the integral membrane ABC transporter P-glycoprotein and the cholesterol metabolic pathway has been proposed [10]. In vitro, nonspecific inhibitors of Pgp inhibit cholesterol esterification and trafficking [5-7], while in vivo research suggests hepatic accumulation and esterification are enhanced in Mdr1a-/-/1b-/- mice [8]. Our research has demonstrated that mice lacking in P-glycoprotein do not exhibit alterations in hepatic total cholesterol storage, circulating plasma total cholesterol levels, or total cholesterol concentration in the bile when compared to control animals on either a normal (25% calories from dietary fat) or high fat (45% calories from dietary fat) diet. However, Mdr1a-/-/1b-/- mice exhibit increased hepatic LXRalpha protein expression and an elevation in fecal cholesterol concentration when compared to controls.
###end p 36
###begin p 37
###xml 271 273 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 441 443 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1135 1136 1115 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 252 255 <span type="species:ncbi:10116">rat</span>
###xml 283 286 <span type="species:ncbi:10116">rat</span>
###xml 705 709 <span type="species:ncbi:10090">mice</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
###xml 862 866 <span type="species:ncbi:10090">mice</span>
###xml 997 1001 <span type="species:ncbi:10090">mice</span>
###xml 1033 1037 <span type="species:ncbi:10090">mice</span>
LXRs are "cholesterol sensors" which, in response to excess cholesterol, stimulate its transport to the liver and facilitate biliary excretion. Various saturated and unsaturated fatty acids are also observed to increase LXRalpha expression in cultured rat hepatoma cells[11]. In the rat, high-fat diet and fasting are associated with an up-regulation of hepatic LXRa expression, likely through the elevation of the plasma fatty acid levels [12]. To examine the interplay between P-glycoprotein and the cholesterol metabolic pathway, we utilized a high fat, normal cholesterol diet to upregulate LXRalpha without affecting dietary cholesterol. Our data indicate that administration of a chronic HF diet to mice results in a significant upregulation of LXRalpha protein expression when compared to the NF diet wild type mice. In addition, P-glycoprotein deficient mice fed a normal chow diet exhibit an equivalent statistically significant increase in LXRalpha expression when compared to wild type mice. When P-glycoprotein deficient mice are placed on a chronic HF diet, no further upregulation in LXRalpha expression is observed (Fig 3).
###end p 37
###begin p 38
###xml 51 53 51 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 277 279 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 505 507 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 653 658 626 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 658 661 631 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 662 664 635 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 664 668 637 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 127 132 <span type="species:ncbi:9606">human</span>
###xml 328 333 <span type="species:ncbi:10090">mouse</span>
###xml 410 416 <span type="species:ncbi:10090">murine</span>
###xml 668 673 <span type="species:ncbi:10090">mouse</span>
In human macrophages, adipocytes, and hepatocytes [13], LXRalpha expression is controlled by an auto-regulatory mechanism. The human LXRalpha gene promoter contains three functional LXR response elements (LXREs), one of which is strongly activated by both LXRalpha and LXRbeta[14]. Although the amount of LXRalpha mRNA in white mouse adipose tissue increases in response to the synthetic LXR agonist T0901317, murine LXRalpha is not autoregulated in other cell types, such as macrophages and hepatocytes [15]. Given the available data, we cannot identify the specific modulator that results in upregulation of hepatic LXRalpha protein expression in the Mdr1a-/-/1b-/- mouse model; however, the data strongly support the P-glycoprotein/cholesterol relationship by demonstrating a significant upregulation of a top-level cholesterol sensing control mechanism, strengthening the link between P-glycoprotein and the cholesterol metabolic pathway.
###end p 38
###begin p 39
###xml 347 349 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 512 514 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 551 556 539 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 556 559 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 560 562 548 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 562 566 550 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 566 571 <span type="species:ncbi:10090">mouse</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
To confirm if a rise in hepatic LXRalpha protein expression translates to increased LXR activity and upregulation of downstream targets, we evaluated the activity of plasma phospholipid transfer protein (PLTP), a known direct target gene of LXRalpha. In mice, disruption of PLTP function dramatically reduces plasma HDL cholesterol concentration [16]. Treatment with LXRalpha agonists is known to result in elevated circulating HDL levels, and it has been suggested that upregulation of PLTP may be responsible [17]. Our findings demonstrate that the Mdr1a-/-/1b-/- mouse model exhibits greater plasma PLTP activity when compared to wild type mice. A trend toward increased PLTP activity with high fat diet is also observed, with activity results closely following hepatic LXRalpha protein expression data.
###end p 39
###begin p 40
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 149 152 149 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 153 155 153 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 155 159 155 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 159 164 <span type="species:ncbi:10090">mouse</span>
As LXR is known to upregulate transcription of proteins involved in cholesterol efflux pathways, our finding of increased LXR expression in the Mdr1a-/-/1b-/- mouse model when compared to wild type is congruent with the observed increase in fecal total cholesterol content (Fig 2b). However, this fecal cholesterol loss may be due to one or all of the following: increased cholesterol efflux from the liver via the bile (mediated by the heterodimeric pair of proteins ABCG5 and 8; [18]); an increase in cholesterol efflux from the enterocyte into the intestinal lumen via ABCA1 [19] or intestinal ABCG5/8 [20]; or a decrease in cholesterol uptake from the intestinal lumen by a yet-unknown protein-facilitated mechanism.
###end p 40
###begin p 41
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 794 799 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 799 802 799 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 803 805 803 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 805 809 805 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 809 814 <span type="species:ncbi:10090">mouse</span>
To examine the potential role of cholesterol efflux from the liver as a contributor to the elevated fecal cholesterol, we quantified hepatic ABCG5 protein expression (Fig. 5) and found no significant difference in protein expression with genotype or diet. As ABCG5/8 heterodimer is the transporter responsible for cholesterol excretion from the liver into the bile, these data are in agreement with our findings of no significant differences in liver cholesterol storage or bile cholesterol concentration. However, we did not measure the rate of bile formation, therefore cannot rule out an increased hepatic cholesterol efflux at this time (although a significant increase in cholesterol efflux via this pathway is not likely, as the protein expression of ABCG5 did not increase in either the Mdr1a-/-/1b-/- mouse model or with a chronic HF diet).
###end p 41
###begin p 42
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1a</italic>
###xml 68 71 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 72 74 72 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1b</italic>
###xml 74 78 74 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
The second possible cause of elevated fecal cholesterol in the Mdr1a-/-/1b-/- mouse model is an increase in cholesterol efflux from the enterocyte into the lumen. It has been demonstrated that activation of the RXR/LXR heterodimer by either a retinoid or LXR agonist effectively blocks cholesterol absorption [20].
###end p 42
###begin p 43
###xml 362 368 362 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Absorption of cholesterol is a three-step process and requires uptake across the luminal membrane followed by cytosolic transport and assembly with lipoproteins, culminating in the subsequent release of cholesterol into lymphatic or systemic circulation. The interruption of any one step along this trafficking route with compromise the absorptive process. Repa et al (2000) attribute the RXR/LXR heterodimer-induced decrease in cholesterol absorption to an observed increase in expression of intestinal ABCA1, a gene product responsible for efflux of cellular free cholesterol [19]. A subsequent study revealed that LXR induced upregulation in ABCG5 and G8 protein expression also contributes to decreased cholesterol absorption, suggesting that all three proteins play a role in decreasing cholesterol absorption via increased cholesterol efflux into the intestinal lumen [20].
###end p 43
###begin p 44
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 956 958 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 668 673 <span type="species:ncbi:10090">mouse</span>
A third mechanism that may be responsible for the observed elevation in fecal cholesterol concentration is the decreased uptake of dietary and biliary cholesterol. A number of findings support the presence of a protein-facilitated cholesterol uptake mechanism located at the enterocyte brush border. Firstly, cholesterol uptake appears to be sensitive to protease treatment and is a saturable process [21]. In addition, sterol uptake is highly selective, with significantly greater uptake of cholesterol occurring across the brush border membrane when compared to similar phytosterols [22,23]. The observed variation in the cholesterol absorption phenotype in various mouse strains, and the development of a specific cholesterol inhibitor, ezetimibe, are strongly suggestive of a genetic component in the cholesterol absorption process. However, the identity of a specific protein-facilitated cholesterol uptake mechanism has been highly controversial [24-28].
###end p 44
###begin p 45
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1650 1652 1650 1652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
Given the indirect relationship between P-glycoprotein protein expression, activity, and cholesterol uptake, the direct transport of cholesterol across the plasma membrane by Pgp is unlikely. However, we cannot rule out Pgp as a contributor to this process. Pgp has been identified as a functional phospholipid and glycosphingolipid flippase, and is associated with cholesterol microdomains in cell membranes [29-32]. Based on the identification of the cholesterol binding site sequence from a benzodiazepine receptor protein [33], we have conducted a bioinformatics analysis to identify four putative cholesterol binding sites on the cytosolic portion of the P-glycoprotein molecule (Leon et al, in submission). The cytosolic location of these cholesterol binding sites on the p-glycoprotein molecule, combined with the evidence supporting an indirect relationship between P-glycoprotein and cholesterol metabolism, suggest that Pgp may act as a cholesterol "dock" which facilitates the transfer of sterol molecules to cytosolic transport proteins, such as Niemann-Pick C1-like1 (NPC1L1). The cytosolic cholesterol binding sites may facilitate the movement of cholesterol from the exofacial to cytofacial leaflet, assisting in the maintenance of membrane cholesterol asymmetry and supplementing the luminal/exofacial leaflet cholesterol gradient, thus facilitating cholesterol diffusion across the membrane. As P-glycoprotein acts as an efflux transporter and is found in the luminal surface of epithelial cells, it has the potential to assist in both cholesterol uptake across the enterocyte, as well as facilitate cholesterol efflux in the liver [29].
###end p 45
###begin title 46
Conclusion
###end title 46
###begin p 47
The establishment of a direct link between P-glycoprotein and cholesterol metabolic pathway remains elusive. However, the data presented here further substantiate the connection between this membrane-bound protein and cholesterol transport. We have observed a significant increase in cholesterol efflux in P-glycoprotein deficient animals and established that the lack of P-glycoprotein results in alterations in the top level of the cholesterol metabolic pathway via increased expression of LXRalpha, a nuclear hormone crucial in orchestrating the complex processes involved in the trafficking of cholesterol. We have further postulated a potential mechanism by which P-glycoprotein may facilitate cholesterol transport across the membrane and, depending on the location of expression, supplement both uptake and efflux of sterol molecules.
###end p 47
###begin title 48
Authors' contributions
###end title 48
###begin p 49
All authors have read and approve of the final manuscript. SJT designed the study, carried out the plasma cholesterol and PLTP assays, EW carried out the Western blot analyses for LXR and ABCG5 and conducted fecal lipid extraction and fecal cholesterol assays, SDL was responsible for animal husbandry, tissue collection and participated in the design of the study and interpretation of results, KMW participated in study coordination. This work was supported by Canadian Institutes of Health Research (CIHR) grant MOP-86447 to KMW and SJT.
###end p 49
###begin title 50
Acknowledgements
###end title 50
###begin p 51
The authors acknowledge the significant assistance of Miguel Pacheco, Julian Kaye and the staff of the Animal Resource Unit. This research was supported by a Canadian Institutes of Health Research (CIHR) grant to SJT and KMW.
###end p 51
###begin article-title 52
The role of orphan nuclear receptors in the regulation of cholesterol homeostasis
###end article-title 52
###begin article-title 53
Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism
###end article-title 53
###begin article-title 54
A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily
###end article-title 54
###begin article-title 55
The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research
###end article-title 55
###begin article-title 56
Triacylglycerol-rich lipoprotein cholesterol is derived from the plasma membrane in CaCo-2 cells
###end article-title 56
###begin article-title 57
Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis
###end article-title 57
###begin article-title 58
Overexpression of MDR1 in an intestinal cell line results in increased cholesterol uptake from micelles
###end article-title 58
###begin article-title 59
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Decreased hepatic accumulation and enhanced esterification of cholesterol in mice deficient in mdr1a and mdr1b P-glycoproteins
###end article-title 59
###begin article-title 60
A simple method for the isolation and purification of total lipides from animal tissues
###end article-title 60
###begin article-title 61
Does p-glycoprotein play a role in gastrointestinal absorption and cellular transport of dietary cholesterol?
###end article-title 61
###begin article-title 62
Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha
###end article-title 62
###begin article-title 63
Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis
###end article-title 63
###begin article-title 64
###xml 54 59 <span type="species:ncbi:9606">human</span>
Liver X receptor (LXR) regulation of the LXRa gene in human macrophages
###end article-title 64
###begin article-title 65
###xml 13 18 <span type="species:ncbi:9606">human</span>
Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism
###end article-title 65
###begin article-title 66
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
Tissue-specific autoregulation of the LXRa gene facilitates induction of apoE in mouse adipose tissue
###end article-title 66
###begin article-title 67
Phospholipid transfer protein is regulated by liver X receptors in vivo
###end article-title 67
###begin article-title 68
Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels
###end article-title 68
###begin article-title 69
The ABC of hepatic and intestinal cholesterol transport
###end article-title 69
###begin article-title 70
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
###end article-title 70
###begin article-title 71
Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta
###end article-title 71
###begin article-title 72
Cholesterol-transfer protein located in the intestinal brush-border membrane. Partial purification and characterization
###end article-title 72
###begin article-title 73
###xml 68 72 <span type="species:ncbi:10116">rats</span>
Discrimination between cholesterol and sitosterol for absorption in rats
###end article-title 73
###begin article-title 74
Comparison of cholesterol and sitosterol uptake in different brush border membrane models
###end article-title 74
###begin article-title 75
Regulation of Intestinal Cholesterol Absorption
###end article-title 75
###begin article-title 76
Cholesterol/phospholipid interactions in hybrid bilayer membranes
###end article-title 76
###begin article-title 77
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption
###end article-title 77
###begin article-title 78
The target of ezetimibe is Niemann Pick C1-like1 (NPC1L1)
###end article-title 78
###begin article-title 79
Multiple plasma membrane receptors but not NPC1L1 mediate high-affinity, ezetimibe-sensitive cholesterol uptake into the intestinal brush border membrane
###end article-title 79
###begin article-title 80
The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane
###end article-title 80
###begin article-title 81
P-Glycoprotein is localized in intermediate-density membrane microdomains distinct from classical lipid rafts and caveolar domains
###end article-title 81
###begin article-title 82
Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains
###end article-title 82
###begin article-title 83
Cholesterol: Coupling between membrane microenvironment and ABC transporter activity
###end article-title 83
###begin article-title 84
Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern
###end article-title 84

